Oral Buccal Mucosa Transmucosal Absorption and Irritation Testing

Oral buccal mucosa transmucosal absorption and irritation testing evaluates whether products applied inside the mouth, such as oral care formulations, buccal drug delivery systems, and mucosa-contacting medical devices, can transport active ingredients across the cheek mucosa and induce local tissue reactions. These tests are performed in accordance with recognized frameworks such as the ISO 10993 series, ISO 7405, and OECD test guidelines, and are essential for regulatory submissions, formulation optimization, and consumer safety assurance. This article explains the technical principles, sample types, test items, methodologies, and applications of buccal mucosa absorption and irritation testing.

Technical Overview

The buccal mucosa is the non-keratinized, stratified squamous epithelium that lines the inner surface of the cheeks. Compared with skin, it is thinner, highly vascularized, and possesses a relatively permeable barrier, which allows many compounds to be absorbed rapidly into the systemic circulation. While this permeability is advantageous for buccal drug delivery, it also increases the risk of local irritation, inflammation, and unintended systemic exposure for products that contact the oral cavity.

Oral buccal mucosa transmucosal absorption and irritation testing is a biocompatibility and safety evaluation designed to answer two key questions: whether a test article penetrates the buccal membrane and to what extent, and whether it provokes adverse local reactions such as erythema, edema, epithelial erosion, or inflammatory mediator release. The evaluation is typically conducted by accredited third-party laboratories under quality management systems such as GLP or ISO/IEC 17025, following the biological evaluation framework of ISO 10993-1, the irritation test requirements of ISO 10993-23 (which superseded the irritation content of ISO 10993-10), the dental device guidance of ISO 7405, the sample preparation rules of ISO 10993-12, and adapted OECD guidelines for in vitro absorption and irritation testing. In China, the corresponding national standards are the GB/T 16886 series, including GB/T 16886.10 and GB/T 16886.23.

Testing Samples

Oral Care and Consumer Products

This category includes toothpaste, mouthwash and oral rinse formulations, oral sprays, breath freshening strips, whitening gels, denture adhesives, medicated chewing gum, and lozenges. These products undergo prolonged or repeated contact with the buccal mucosa, making local irritation and absorption assessment a core element of their safety profiles.

Pharmaceutical and Drug Delivery Products

Buccal tablets, mucoadhesive films and patches, sublingual and buccal sprays, orally disintegrating formulations, and other oral transmucosal delivery systems are tested to characterize both their permeation behavior and their local tolerability at the intended contact site and exposure duration.

Nicotine and Related Products

Nicotine pouches, smokeless tobacco products, and other orally consumed nicotine formats are placed directly against the buccal mucosa for extended periods. Absorption kinetics and mucosal irritation data are frequently required elements of regulatory notification and premarket submissions for such products.

Medical and Dental Devices

Dental cements, impression materials, orthodontic appliances, mouthguards, obturators, and other devices categorized as mucosal membrane-contacting devices under ISO 10993-1 require irritation testing as part of their biological evaluation. Test articles may be evaluated as finished products, materials, or extracts prepared in polar and non-polar media.

Testing Items

A comprehensive buccal mucosa safety evaluation typically encompasses the following endpoints, which can be selected individually or combined depending on the product type and regulatory context:

• Acute buccal mucosa irritation testing following single or short-term exposure
• Repeated-exposure mucosal irritation testing over extended application periods, such as 14 to 28 days
• Primary Irritation Index (PII) calculation and mucosal response grading based on macroscopic observation
• Histopathological examination of mucosal tissue, including epithelial integrity, keratinization changes, and inflammatory cell infiltration
• In vitro tissue viability testing using reconstructed human oral epithelium (RhOE) models with MTT or similar viability assays
• ET50 determination, the exposure time required to reduce tissue viability by 50 percent
• Inflammatory mediator release, including IL-1alpha, IL-6, IL-8, and PGE2
• Transepithelial electrical resistance (TEER) measurement as an indicator of barrier function
• Ex vivo transmucosal permeation parameters, including cumulative permeated amount, steady-state flux, apparent permeability coefficient, and mucosal retention
• Quantification of permeated compounds in receptor fluid using HPLC or LC-MS/MS analytical methods

Testing Methods

In Vivo Buccal Mucosa Irritation Test

The Syrian golden hamster cheek pouch model is the most widely accepted in vivo method for evaluating irritation on the oral mucosa. The test article, or an extract prepared according to ISO 10993-12, is applied directly to the everted cheek pouch for a defined contact period, typically once or twice daily across an observation window of several days to several weeks. Mucosal surfaces are scored macroscopically for erythema, eschar, and edema using standardized grading scales, and the Primary Irritation Index is calculated as the sum of all scores divided by the number of observations. Negative controls, such as the extraction vehicle, and positive controls, such as a known mucosal irritant, are included to validate assay sensitivity. At termination, tissues are harvested for histopathological analysis to confirm and grade the observed responses.

In Vitro Reconstructed Human Oral Epithelium Model

As part of the global shift toward animal-free testing under the 3Rs principle, commercially available reconstructed human oral epithelium models are increasingly used for irritation screening. These three-dimensional tissue constructs consist of human-derived oral epithelial cells cultured at an air-liquid interface, closely mimicking the structure and barrier properties of native buccal mucosa. The test article is applied topically for defined exposure periods, after which tissue viability is measured using MTT reduction. Dose-response relationships, ET50 values, and cytokine release profiles provide a quantitative basis for classifying irritation potential. The method follows the general principles of OECD Test Guideline 439 adapted to the oral mucosa context.

Ex Vivo Transmucosal Permeation Testing

Transmucosal absorption is characterized using Franz diffusion cells or flow-through diffusion cells mounted with excised buccal mucosa, most commonly porcine buccal tissue because of its well-documented structural and permeability similarity to human mucosa. The test formulation is applied to the donor compartment, while the receptor compartment contains an appropriate physiological buffer maintained at 37 degrees Celsius with continuous stirring to ensure sink conditions. Receptor fluid is sampled at serial time points over the test duration, typically 6 to 24 hours, and analyzed by validated HPLC or LC-MS/MS methods. The cumulative permeated amount per unit area is plotted against time, from which steady-state flux and the apparent permeability coefficient are derived. Membrane integrity is verified before and after the experiment using TEER or marker compound permeation. The methodological framework follows OECD Test Guideline 428, adapted for mucosal membranes.

Sample Preparation and Extraction

For devices and materials that cannot be tested directly, extracts are prepared according to ISO 10993-12. Polar media such as physiological saline and non-polar media such as sesame oil are used to extract both hydrophilic and lipophilic leachables. Standard extraction conditions include 37 degrees Celsius for 72 hours, with extraction ratios based on material mass or device surface area. The pH, osmolality, and sterility of test solutions are documented to ensure that observed effects reflect the test article rather than the test conditions themselves.

Applications

Buccal mucosa absorption and irritation testing supports a wide range of product development and regulatory objectives:

• Biological evaluation dossiers for medical devices with mucosal membrane contact, satisfying the irritation requirements of the ISO 10993-1 test matrix
• Safety assessment files for oral care and oral hygiene products submitted to national cosmetic and consumer product regulatory authorities
• Premarket submissions and notification programs for novel nicotine and orally consumed products in multiple jurisdictions
• Pharmaceutical development support for buccal and sublingual delivery systems, including excipient selection and formulation refinement
• Comparative benchmarking of test formulations against reference products to support mildness and tolerability claims
• Investigation of adverse event reports and post-market safety monitoring
• Screening of new raw materials and functional ingredients prior to incorporation into oral products

FAQ

What standards govern buccal mucosa irritation testing?

The primary framework is the ISO 10993 series, particularly ISO 10993-1 for test selection, ISO 10993-12 for sample preparation, and ISO 10993-23 for irritation testing, which replaced the irritation content formerly covered by ISO 10993-10. Dental materials are additionally evaluated under ISO 7405. In vitro absorption studies follow OECD Test Guideline 428, and in vitro irritation studies draw on OECD Test Guideline 439 principles. In China, the GB/T 16886 series provides equivalent national standards.

How is the irritation result interpreted?

In vivo results are reported as graded mucosal responses and a calculated Primary Irritation Index. Low indices indicate negligible irritation potential, while progressively higher values indicate slight, moderate, or severe irritation, and these classifications are interpreted alongside histopathological findings. In vitro results are interpreted by comparing tissue viability and ET50 values against established classification thresholds.

Why is porcine buccal mucosa commonly used for permeation testing?

Porcine buccal mucosa shares strong structural, histological, and permeability similarities with human buccal tissue, is available in sufficient quantities from food industry sources, and is accepted by regulatory reviewers as a physiologically relevant membrane for ex vivo diffusion studies.

Can in vitro methods fully replace animal testing?

Reconstructed human oral epithelium models are widely accepted for screening and, in some regulatory contexts, for standalone hazard classification. However, for medical device biological evaluations and certain submission types, in vivo confirmation may still be requested, so the appropriate test strategy should be confirmed with the regulatory authority and the accredited third-party laboratory on a case-by-case basis.

How much sample is required for testing?

Required quantities depend on the test design. In vivo irritation studies generally require sufficient material for repeated application throughout the observation period, while ex vivo permeation studies require enough formulation to charge multiple diffusion cells with replicates. Laboratories typically confirm specific volume and mass requirements during the protocol review stage.

What is the typical project timeline?

Ex vivo permeation studies and in vitro epithelium assays are usually completed within two to four weeks after sample receipt and method validation. In vivo irritation studies, including an acclimatization period, dosing phase, observation window, and histopathology, generally require four to eight weeks. Analytical method development and validation for quantifying the permeated compound may extend the schedule and should be planned in advance.